Sources
Every quotation on this site about where or how a medicine is injected is a word-for-word quote from that medicine's FDA label, as published on DailyMed by the U.S. National Library of Medicine. The short lines the site writes itself only say what those labels say or do not say, and nothing is filled in from other sources.
Before each update, a script fetches every page below and fails if any quote is not found on it exactly, or if the label's revision date has changed. Last checked November 10, 2026.
-
Ozempic (semaglutide), Novo Nordisk
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
Label revised 5/2026. Quoted from: Prescribing information; Instructions for Use, prefilled syringe.
FDA marketing status: Drugs@FDA, application NDA209637, one product marked “Discontinued”, six products marked “Prescription”.
-
Wegovy (semaglutide), Novo Nordisk
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Label revised 6/2026. Quoted from: Prescribing information; Instructions for Use, pen; Instructions for Use, prefilled syringe.
FDA marketing status: Drugs@FDA, application NDA215256, 12 products marked “Prescription”.
-
Mounjaro (tirzepatide), Eli Lilly
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
Label revised 8/2026. Quoted from: Prescribing information; Instructions for Use.
FDA marketing status: Drugs@FDA, application NDA215866, 24 products marked “Prescription”.
-
Zepbound (tirzepatide), Eli Lilly
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Label revised 8/2026. Quoted from: Prescribing information; Instructions for Use.
FDA marketing status: Drugs@FDA, application NDA217806, 24 products marked “Prescription”.
-
Trulicity (dulaglutide), Eli Lilly
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
Label revised 3/2026. Quoted from: Prescribing information; Instructions for Use.
FDA marketing status: Drugs@FDA, application BLA125469, four products marked “Prescription”.
-
Bydureon BCise (exenatide extended-release), AstraZeneca
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5
Label revised 5/2025. Quoted from: Medication Guide; Instructions for Use; Prescribing information.
Discontinued FDA lists it as discontinued (Drugs@FDA, application NDA209210, checked November 10, 2026). Its label page is still on DailyMed.
FDA marketing status: Drugs@FDA, application NDA209210, one product marked “Discontinued”.
-
Victoza (liraglutide), Novo Nordisk
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
Label revised 10/2025. Quoted from: Prescribing information; Instructions for Use.
FDA marketing status: Drugs@FDA, application NDA022341, one product marked “Prescription”.
-
Saxenda (liraglutide), Novo Nordisk
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
Label revised 6/2026. Quoted from: Prescribing information.
FDA marketing status: Drugs@FDA, application NDA206321, one product marked “Prescription”.
Supply status
Shortage and discontinuation status comes from FDA's Drug Shortages database (FDA Drug Shortages), read through openFDA, and is checked against it before each update by a second script. The same script reads each medicine's marketing status from Drugs@FDA, through openFDA, and fails if FDA has changed it; last checked November 10, 2026. Source: FDA Drug Shortages database, via openFDA. Do not rely on openFDA to make decisions regarding medical care; check with your pharmacy.